We are live on
!
Find out more
KAM
Kazazian Asset Management Portfolio holdings
AUM
$91.5M
1-Year Est. Return
35.36%
This Fund
S&P 500
This Quarter
Est. Return
-3.92%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.4M
AUM Growth
-$2.44M
(-2.5%)
Cap. Flow
+$4.55M
Cap. Flow
% of AUM
4.76%
Top 10 Holdings %
Top 10 Hldgs %
49.5%
Holding
93
New
11
Increased
17
Reduced
38
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$2.15M |
| 2 |
Biogen
BIIB
|
+$1.77M |
| 3 |
Intel
INTC
|
+$1.21M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$993K |
| 5 |
Oracle
ORCL
|
+$903K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$976K |
| 2 |
PPLI
People Inc
PPLI
|
+$900K |
| 3 |
Micron Technology
MU
|
+$884K |
| 4 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$836K |
| 5 |
General Motors
GM
|
+$688K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.25% |
| 2 | Consumer Discretionary | 9.29% |
| 3 | Financials | 8.39% |
| 4 | Technology | 6.79% |
| 5 | Communication Services | 5.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
iShares MSCI Emerging Markets ETF
EEM
$29.5B
| $10.2M | 10.73% |
212,000
-8,000
| -4% | -$392K |
|
2
State Street SPDR S&P 500 ETF Trust
SPY
$823B
| $8.38M | 8.78% |
31,852
-987
| -3% | -$269K |
|
|
3
General Motors
GM
$76.8B
| $6.1M | 6.4% |
167,977
-16,958
| -9% | -$688K |
|
|
4
Biogen
BIIB
$30.7B
| $4.09M | 4.28% |
14,929
+5,700
| +62% | +$1.77M |
|
5
Alphabet (Google) Class C
GOOG
$4.32T
| $3.78M | 3.96% |
73,200
-5,940
| -8% | -$328K |
|
6
Apple
AAPL
$4.57T
| $3.46M | 3.63% |
82,520
+20,836
| +34% | +$897K |
|
7
Citigroup
C
$226B
| $3.29M | 3.44% |
48,686
-3,129
| -6% | -$235K |
|
8
DigitalBridge
DBRG
$2.95B
| $2.69M | 2.81% |
119,437
+5,264
| +5% | +$171K |
|
|
BPMC
9
DELISTED
Blueprint Medicines
BPMC
| $2.63M | 2.75% |
28,646
| – | – |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.6M | 2.72% |
23,283
+6,000
| +35% | +$717K |
|
|
11
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.51B
| $2.11M | 2.21% |
+15,000
| New | +$2.15M |
|
|
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.93M | 2.02% |
36,529
+17,012
| +87% | +$993K |
|
13
Barclays
BCS
$94.1B
| $1.9M | 1.99% |
167,917
+22,524
| +15% | +$246K |
|
|
RESI
14
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $1.87M | 1.96% |
185,966
-35,916
| -16% | -$382K |
|
15
Bausch Health
BHC
$2.34B
| $1.85M | 1.93% |
115,970
-11,597
| -9% | -$216K |
|
16
Nektar Therapeutics
NKTR
$2.58B
| $1.78M | 1.87% |
1,117
-184
| -14% | -$237K |
|
17
iShares MSCI Germany ETF
EWG
$1.62B
| $1.68M | 1.76% |
52,401
-4,692
| -8% | -$156K |
|
|
CS
18
DELISTED
Credit Suisse Group
CS
| $1.65M | 1.72% |
98,064
-9,936
| -9% | -$182K |
|
19
iShares Silver Trust
SLV
$30.7B
| $1.59M | 1.67% |
103,415
-34,331
| -25% | -$542K |
|
20
Alibaba
BABA
$308B
| $1.53M | 1.6% |
8,313
-718
| -8% | -$135K |
|
21
Baidu
BIDU
$37.2B
| $1.35M | 1.42% |
6,052
-317
| -5% | -$78.1K |
|
|
22
Intel
INTC
$513B
| $1.32M | 1.39% |
+25,408
| New | +$1.21M |
|
|
NS
23
DELISTED
NuStar Energy L.P.
NS
| $1.22M | 1.28% |
60,018
+9,518
| +19% | +$255K |
|
24
Bristol-Myers Squibb
BMY
$132B
| $1.18M | 1.24% |
18,721
-1,171
| -6% | -$75.3K |
|
25
Global X MLP ETF
MLPA
$2.26B
| $1.17M | 1.23% |
23,003
+6,086
| +36% | +$355K |
|
Similar funds
MRP
ITG
MA
AW
SPCM
ML
ICM
ACMC
Kazazian Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Kazazian Asset Management held 93 positions worth $95.4M, down 2.5% from $97.9M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Kazazian Asset Management deployed $4.55M of net new capital in Q1 2018, opening 11 new positions and adding to 17 existing holdings. Its largest new stake was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was General Motors, an estimated $688K trimmed.
- Kazazian Asset Management's largest Q1 2018 buy was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.
- Kazazian Asset Management added most to Biogen in Q1 2018, an estimated $1.77M increase.
- Kazazian Asset Management's biggest Q1 2018 reduction was General Motors, cutting an estimated $688K.
- Kazazian Asset Management fully exited Vertex Pharmaceuticals in Q1 2018, selling an estimated $976K.
- Kazazian Asset Management's ten largest holdings make up 50% of its $95.4M portfolio in Q1 2018.
- Kazazian Asset Management opened 11 new positions and closed 8 in Q1 2018.
- Kazazian Asset Management's portfolio value fell 2.5% quarter-over-quarter to $95.4M.
Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.